GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's disease, which in the future ...

A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and ...

AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.